Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05517226
Other study ID # D5671C00008
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 6, 2022
Est. completion date February 27, 2023

Study information

Verified date March 2023
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous injection of cotadutide in participants with mild, moderate or severe hepatic impairment compared to participants with normal hepatic function.


Description:

This study will consist of four cohorts (Cohort 1, Cohort 2, Cohort 3, and Cohort 4). Participants will be assigned to each of the cohorts as per Child-Pugh classification: - Cohort 1: Mild hepatic impairment (Child-Pugh A), cotadutide 50 μg - Cohort 2: Moderate hepatic impairment (Child-Pugh B), cotadutide 50 μg - Cohort 3: Severe hepatic impairment (Child-Pugh C), cotadutide 50 μg - Cohort 4: Normal hepatic function, cotadutide 50 μg


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date February 27, 2023
Est. primary completion date February 27, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Participant must be = 18 to = 85 years of age at the time of signing the Informed Consent Form (ICF). - Body mass index = 18 kg/m2 to < 40 kg/m2. - Female participants of childbearing potential must use at least one highly effective form of birth control. - Capable of giving signed informed consent. Participants with hepatic impairment only - Diagnosis of chronic (= 6 months) and stable hepatic impairment (eg, no clinically significant change in signs, symptoms, or laboratory parameters of hepatic disease status within 30 days prior to study Screening). Exclusion Criteria: All participants - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to cotadutide. - Any clinically important abnormalities in rhythm, conduction or morphology of the 12-lead resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QT interval corrected for heart rate using Fridericia's formula (QTcF), including abnormal ST-T-wave morphology, or left ventricular hypertrophy 1. Prolonged QTcF > 470 ms or family history of long QT syndrome. 2. PR (PQ) interval shortening < 120 ms. 3. PR (PQ) interval prolongation (> 220 ms) intermittent or permanent second or third degree atrioventricular (AV) block, or AV dissociation. 4. Persistent or intermittent complete bundle branch block, or intraventricular conduction delay with QRS > 119 ms. - Any evidence of additional severe or uncontrolled systemic disease or laboratory finding that makes it unsafe for the participant to participate in the study. - Impaired renal function, defined as estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m2 at Screening. - Any positive result on Screening for serum hepatitis B surface antigen, anti-Core HBV antibody, hepatitis C antibody, or human immunodeficiency virus (HIV). - Any sign and confirmation of coronavirus disease 2019 (COVID19) infection: - Participants with concurrent or previous use of a glucagon-like peptide-1 (GLP1) receptor agonist. - Use of prohibited prescribed or nonprescribed medication during the 2 weeks prior to the first administration of Investigational Medicinal Product (IMP) or longer if the medication has a long half-life. - History of neoplastic disease within 5 years prior to Screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer. - Presence of hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity. Participants with hepatic impairment only - Severe portal hypertension or surgical porto-systemic shunts. - Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver. - Clinically relevant hepatic encephalopathy. - Severe ascites defined as ascites requiring paracentesis and albumin at 4-week intervals or less. - Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the 28-day Screening period. - Post liver transplantation. - Platelet count < 50 × 109/L and/or neutrophil count < 1.2 × 109/L and/or hemoglobin < 8.5 g/dL or INR >2.3. Participants with normal hepatic function only - History or presence of hepatic disease or evidence of other known forms of known chronic liver disease. - History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. - Urinary albumin-to-creatinine ratio > 3 mg/µmol.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Cotadutide
Participants will receive cotadutide subcutaneously.

Locations

Country Name City State
United States Research Site Hialeah Florida
United States Research Site San Antonio Texas
United States Research Site San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Parexel

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum observed plasma (peak) drug concentration [Cmax] The Cmax of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed. Day 1 to Day 3
Primary Area under plasma concentration time curve from zero to infinity (AUCinf) The AUCinf of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed. Day 1 to Day 3
Primary Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast) The AUClast of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed. Day 1 to Day 3
Primary Time to reach peak or maximum observed concentration or response following drug administration (tmax) The tmax of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed. Day 1 to Day 3
Primary Terminal half-life (t½?z) The t½?z of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed. Day 1 to Day 3
Primary Apparent total body clearance (CL/F) The CL/F of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed. Day 1 to Day 3
Primary Apparent volume of distribution based on the terminal phase (Vz/F) The Vz/F of a single dose of cotadutide in participants with mild, moderate, or severe hepatic impairment compared to those with normal hepatic function will be assessed. Day 1 to Day 3
Secondary Number of participants with Adverse Events (AEs) The safety, and tolerability of a single dose of cotadutide in participants with hepatic impairment will be assessed. From time of first dose to the final follow-up visit (Day 29)
Secondary Incidence of ADAs (anti-drug antibodies) The safety, and tolerability of a single dose of cotadutide in participants with hepatic impairment will be assessed. From time of first dose to the final follow-up visit (Day 29)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05009680 - A Single and Repeat Dose Trial in Participants With Hepatic Impairment Phase 1/Phase 2
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT03983161 - A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment Phase 1
Completed NCT04546789 - Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK Phase 1
Completed NCT03282513 - A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function Phase 1
Recruiting NCT05976321 - A Study of TAK-279 in Adults With or Without Liver Damage Phase 1
Completed NCT04473664 - A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment Phase 1
Recruiting NCT05484206 - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Phase 1
Completed NCT03290443 - A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. Phase 1
Completed NCT02245243 - Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment Phase 1
Completed NCT02244827 - Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment Phase 1
Completed NCT02004587 - Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers Phase 1
Completed NCT01621633 - A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers Phase 2
Completed NCT01493869 - Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects Phase 1
Completed NCT04482270 - A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function Phase 1
Completed NCT02115347 - Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) Phase 1
Recruiting NCT04950764 - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Phase 1
Completed NCT06161259 - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment Phase 1
Completed NCT05481411 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment Phase 1
Completed NCT05409911 - A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants Phase 1